newsfilter
← Latest News
Business Wire·

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

~ CASI Pharmaceuticals acquires global rights to CB-5339, a clinical stage VCP/p97 inhibitor in development for oncology indications ~ Eikon Therapeutics acquires pre-clinical assets spanning multiple targets Cleave